Top Markets
#1 Black Phoenix Black Phoenix +198.17%
#2 Islamic Coin Islamic Coin +158.03%
#3 Glidr Glidr +84.34%
#4 BasedHype BasedHype +38.64%
#5 Gold Park Gold Park +37.95%
#6 Acurast Acurast +29.31%
#7 Cryptopia Cryptopia +21.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +15.62%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +13.63%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Panacos Pharmaceuticals, Inc. Panacos Pharmaceuticals, Inc.

Panacos Pharmaceuticals, Inc.

PANC
Rank in Stocks #42054
Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm... Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans. The company's scientific methodology concentrates on identifying novel targets within the viral life cycle, specifically focusing on processes like virus maturation and fusion. Currently, their product portfolio includes advanced initiatives, such as second- and third-generation programs, centered on inhibiting HIV maturation. Founded in 1999, the company's main operations are situated in Watertown, Massachusetts.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$5.37K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Panacos Pharmaceuticals, Inc. (PANC)

Category

Healthcare
Revenue for Panacos Pharmaceuticals, Inc. (PANC)
Revenue in Aug 2026 TTM: 0
According to Panacos Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Panacos Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE